122 related articles for article (PubMed ID: 15572728)
1. Targeted for destruction: the molecular basis for development of novel therapeutic strategies in renal cell cancer.
Srinivasan R; Linehan WM
J Clin Oncol; 2005 Jan; 23(3):410-2. PubMed ID: 15572728
[No Abstract] [Full Text] [Related]
2. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
VanOosten RL; Earel JK; Griffith TS
Cancer Gene Ther; 2006 Jun; 13(6):628-32. PubMed ID: 16456549
[TBL] [Abstract][Full Text] [Related]
3. The multidrug resistance gene in renal cell carcinoma.
Klein EA
Semin Urol; 1989 Nov; 7(4):207-14. PubMed ID: 2575783
[No Abstract] [Full Text] [Related]
4. What is new in kidney cancer?
Kirkali Z
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1753-5. PubMed ID: 19954286
[TBL] [Abstract][Full Text] [Related]
5. New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance.
Rini BI
Clin Cancer Res; 2010 Mar; 16(5):1348-54. PubMed ID: 20179240
[TBL] [Abstract][Full Text] [Related]
6. New therapeutic developments in renal cell cancer.
Prenen H; Gil T; Awada A
Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
[TBL] [Abstract][Full Text] [Related]
7. Everolimus and pazopanib: two new drugs for renal cell cancer.
Med Lett Drugs Ther; 2010 May; 52(1337):33-4. PubMed ID: 20431519
[No Abstract] [Full Text] [Related]
8. Recent investigations of histone deacetylase inhibitors in renal cell carcinoma.
Pili R
Clin Adv Hematol Oncol; 2009 Apr; 7(4):252-4. PubMed ID: 19521328
[No Abstract] [Full Text] [Related]
9. Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities.
Hansel DE; Rini BI
Expert Rev Anticancer Ther; 2008 Jun; 8(6):895-905. PubMed ID: 18533799
[TBL] [Abstract][Full Text] [Related]
10. Molecularly targeted therapies for renal cell cancer: TRAIL research advances.
Buttyan R; Mian BM
J Urol; 2007 May; 177(5):1606. PubMed ID: 17437767
[No Abstract] [Full Text] [Related]
11. Multiple drug resistance: biologic basis and clinical significance in renal-cell carcinoma.
Chapman AE; Goldstein LJ
Semin Oncol; 1995 Feb; 22(1):17-28. PubMed ID: 7855615
[No Abstract] [Full Text] [Related]
12. Molecular genetic events associated with renal cell carninoma and its implication to treatment by molecular target therapy.
Kishida T; Yao M; Uemura H; Ohlmann C; Tomita Y; Bukowski RM; Naito S
Int J Urol; 2010 Mar; 17(3):198-205. PubMed ID: 20409215
[No Abstract] [Full Text] [Related]
13. Prognostic implications of polymorphisms and interleukin-2 therapy for renal cell carcinoma.
Gardner TA; Logan T
J Urol; 2009 Aug; 182(2):425-6. PubMed ID: 19524946
[No Abstract] [Full Text] [Related]
14. Molecular pathways in renal cell carcinoma--rationale for targeted treatment.
Kim WY; Kaelin WG
Semin Oncol; 2006 Oct; 33(5):588-95. PubMed ID: 17045088
[TBL] [Abstract][Full Text] [Related]
15. Induction of apoptosis in renal cell carcinoma by reactive oxygen species: involvement of extracellular signal-regulated kinase 1/2, p38delta/gamma, cyclooxygenase-2 down-regulation, and translocation of apoptosis-inducing factor.
Ambrose M; Ryan A; O'Sullivan GC; Dunne C; Barry OP
Mol Pharmacol; 2006 Jun; 69(6):1879-90. PubMed ID: 16543392
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of hypoxia inducible factor in renal cell carcinoma.
Smaldone MC; Maranchie JK
Urol Oncol; 2009; 27(3):238-45. PubMed ID: 19414111
[TBL] [Abstract][Full Text] [Related]
17. Molecular targeted therapies for renal cell carcinoma.
Graham SD; Warden ME; Lou J
Can J Urol; 2007 Dec; 14 Suppl 1():48-52. PubMed ID: 18163945
[TBL] [Abstract][Full Text] [Related]
18. Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma.
Morikawa T; Sugiyama A; Kume H; Ota S; Kashima T; Tomita K; Kitamura T; Kodama T; Fukayama M; Aburatani H
Clin Cancer Res; 2007 Oct; 13(19):5703-9. PubMed ID: 17908959
[TBL] [Abstract][Full Text] [Related]
19. Targeted agents for the treatment of advanced renal cell carcinoma.
Stadler WM
Cancer; 2005 Dec; 104(11):2323-33. PubMed ID: 16240452
[TBL] [Abstract][Full Text] [Related]
20. Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer.
Porta C
Expert Rev Anticancer Ther; 2006 Jan; 6(1):141-52. PubMed ID: 16375651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
